Interstitial Cystitis
Pelvic floor muscle pain is associated with higher symptom scores and bladder pain perception in women with interstitial cystitis and bladder pain syndrome.
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a heterogeneous, multifactorial disease with a high prevalence of somatic symptoms. A high percentage of women with IC/BPS also experience pelvic floor muscle pain (PFMP).
Does Muscle Pain Induce Alterations in the Pelvic Floor Motor Unit Activity Properties in Interstitial Cystitis/Bladder Pain Syndrome? A High-Density sEMG-Based Study
Monica Albaladejo-Belmonte,1 Michael Houston,2 Nicholas Dias,2 Theresa Spitznagle,3 Henry Lai,4 Yingchun Zhang,2,5,6,7 and Javier Garcia-Casado,1
- Centro de Investigación e Innovación en Bioingeniería (CI2B), Universitat Politècnica de València, Camino de Vera s/n, 46022 Valencia, Spain
- Department of Biomedical Engineering, University of Houston, Houston, TX 77204, USA
- Program in Physical Therapy, Washington University School of Medicine, St. Louis, MO 63108, USA
- Division of Urologic Surgery, Departments of Surgery and Anesthesiology, Washington University School of Medicine, St. Louis, MO 63110, USA
- Department of Biomedical Engineering, University of Miami, Coral Gables, FL 33146, USA
- Desai Sethi Urology Institute, University of Miami, 1120 NW 14th Street, Miami, FL 33136, USA
- Miami Project to Cure Paralysis, University of Miami, 1095 NW 14th Terrace #48, Miami, FL 33136, USA
Transient Receptor Potential Melastatin 8 Contributes to Cystitis-Induced Neuronal Sprouting and Pain Hypersensitivity Through AKT/mTOR Signaling Pathway in Interstitial Cystitis/Bladder Pain Syndrome.
The aim of this study was to investigate the mechanism of TRPM8 in neuroproliferation and pain, as well as the relevance of the Akt/mTOR signaling pathway in mice with IC/BPS.
The model of IC/BPS was established in wild and TRPM8-/- mice.
Bladder instillations vs onabotulinumtoxinA injection for interstitial cystitis/bladder pain syndrome: a randomized clinical trial
Objective: To compare the efficacy of bladder instillations and intradetrusor onabotulinumtoxinA injection for treatment of IC/BPS.
Study design: Patients with O'Leary-Sant (OLS) questionnaire scores of ≥6, meeting clinical criteria for IC/BPS, and desiring procedural management were randomized to bladder instillations or intradetrusor onabotulinumtoxinA injection. The primary outcome was the difference in OLS scores at 2 months posttreatment between groups. Secondary outcomes included evaluation of sexual function, physical/mental health status, pain, patient satisfaction, treatment perception, retreatment, and adverse event rates.
Results: Forty-seven patients were analyzed with 22 randomized to bladder instillations and 25 to onabotulinumtoxinA injection. There were no differences in demographic and clinical characteristics between groups. From baseline to 2 months posttreatment, there was a decrease in OLS subscales in all patients (Interstitial Cystitis Symptom Index [ICSI] -6.3 (confidence interval [CI] -8.54, -3.95), P<.0001; Interstitial Cystitis Problem Index [ICPI] -5.9 (CI -8.18, -3.57), P<.0001). At 2 months posttreatment, patients in the onabotulinumtoxinA group had significantly lower OLS scores compared to those in the bladder instillation group (ICSI 6.3±4.5 [onabotulinumtoxinA] vs 9.6±4.2 [instillation], P=.008; ICPI 5.9±5.1 [onabotulinumtoxinA] vs 8.3±4.0 [instillation], P=.048). The difference in OLS scores between groups did not persist at 6 to 9 months posttreatment. There were no statistically significant differences between baseline and posttreatment time points for the remaining questionnaires. Eight percent of patients who received onabotulinumtoxinA injection experienced urinary retention requiring self-catheterization. Patients who underwent onabotulinumtoxinA injection were significantly less likely to receive retreatment within 6 to 9 months compared to patients who received bladder instillations (relative risk 13.6; 95% CI, 1.92-96.6; P=.0002). There were no differences between groups regarding patient satisfaction, perception of treatment convenience, or willingness to undergo retreatment.
Conclusion: Both onabotulinumtoxinA injection and bladder instillations are safe, effective treatments for patients with IC/BPS, with significant clinical improvement demonstrated at 2 months posttreatment. Our findings suggest that intradetrusor onabotulinumtoxinA injection is a more effective procedural treatment for this condition than bladder instillation therapy and associated with decreased rates of retreatment.
Eva K Welch 1, Katherine L Dengler 2, Angela M DiCarlo-Meacham 3, Joy E Wheat 4, Carissa J Pekny 5, James K Aden 6, Christine M Vaccaro 2
- Department of Gynecologic Surgery & Obstetrics-Urogynecology Division, San Antonio Military Medical Center, Fort Sam Houston, TX.
- Department of Gynecologic Surgery & Obstetrics-Urogynecology Division, Walter Reed National Military Medical Center, Bethesda, MD.
- Department of Gynecologic Surgery & Obstetrics-Urogynecology Division, Naval Medical Center San Diego, San Diego, CA.
- Department of Gynecologic Surgery & Obstetrics-Urogynecology Division, San Antonio Military Medical Center, Fort Sam Houston, TX.
- Department of Gynecologic Surgery & Obstetrics, Walter Reed National Military Medical Center, Bethesda, MD.
- Graduate Medical Education, San Antonio Military Medical Center, Fort Sam Houston, TX.
Purine Nucleoside Phosphorylase as a Target for the Treatment of Interstitial Cystitis/Bladder Pain Syndrome with and without Hunner Lesions - Beyond the Abstract
Bladder Pain Syndrome (BPS): A Comprehensive Review of Treatment Strategies and Management Approaches.
Bladder pain Syndrome presents a multifaceted challenge in contemporary urological practice, marked by LUTS, negative behavioural, sexual, or emotional experiences, and the potential for sexual dysfunction.
Widespread pain phenotypes impact treatment efficacy results in randomized clinical trials for interstitial cystitis/bladder pain syndrome: a Multidisciplinary Approach to the Study of Chronic Pelvic Pain network study.
Pain clinical trials are notoriously complex and often inefficient in demonstrating efficacy, even for known efficacious treatments. A major issue is the difficulty in the a priori identification of specific phenotypes to include in the study population.
A Pain Desensitization Algorithm for Phenotyping and Treating Chronic Pelvic Pain.
Chronic pelvic pain remains challenging for physicians to manage due to central and peripheral sensitization and multiple pain generators including the bladder, pelvic floor, and pudendal nerve. Pain management providers have used nerve blocks for years for diagnosis and treatment.
Interstitial Cystitis Chatter: A Qualitative Evaluation of Bladder Instillation Online.
To qualitatively assess the perception and experiences of bladder instillation for interstitial cystitis among women on Reddit, a widely used anonymous social media platform.
"r/interstitialcystitis," a Subreddit with > 27,000 subscribers, was queried for bladder instillation among women with interstitial cystitis in November 2023.